A report by Science 37 examines key considerations for patient safety and business continuity in the clinical trial industry in light of the ongoing coronavirus pandemic.
Aiming to encourage entry of generic drugs on the market, the US FDA published a finalized guidance that regulates processes for relevant designations and expedited approvals.
The purchase is aimed at expanding the company’s specialty diagnostics offerings in sample preparation technology, assay capabilities, bioinformatics and more.
Innovative Trials is set to work on increasing awareness within patient communities and improving engagement rates on behalf of Christie NHS Foundation Trust.
Raremark’s patient data and demographics will be integrated in TriNetX’s platform to help people with rare conditions access clinical trials and facilitate recruitment.
Filed in 2017, Veeva Systems’ antitrust lawsuit alleges Iqvia has exacted ‘monopoly control’ restricting freedom in clinical trial software and data management.
The US FDA announces shortage of a drug due to a site affected by coronavirus, as it focuses on the protection of the supply chain from outbreak impacts.
As part of its efforts to reach a global settlement to resolve opioid claims, Mallinckrodt will file for Chapter 11 bankruptcy for its specialty generics subsidiary.
US FDA’s 2019 Drugs Trials Snapshots show female participation in clinical trials of the drugs approved during the past year increased, although ethnic diversity remains an issue.
Aiming to support drug developers in issues related to market insights, engagement, and access, Synaptiq enters the market backed by three consultancy agencies.
